Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study

M. Norlin, Jenny ; Hjalte, Frida ; Kruse, Christopher ; Dodel, Richard ; Rosqvist, Kristina LU and Odin, Per LU orcid (2022) In Acta Neurologica Scandinavica 145(6). p.743-752
Abstract

Background: Few studies have investigated the health-related quality of life (HRQoL), resource use and costs in patients with late-stage Parkinson's disease (PD), and data from the Swedish setting are scarce. Objectives: First, we analyse the HRQoL in late-stage PD in Sweden. Second, we analyse the resource use and costs per severity level. Third, we analyse the relationship between costs and physician- and patient reported-outcome measures. Materials and methods: The study was based on Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study. The costs of healthcare contacts, drugs, formal and informal care, and productivity loss were collected over three months. Assessments at baseline were used for outcomes (EQ-5D, Hoehn... (More)

Background: Few studies have investigated the health-related quality of life (HRQoL), resource use and costs in patients with late-stage Parkinson's disease (PD), and data from the Swedish setting are scarce. Objectives: First, we analyse the HRQoL in late-stage PD in Sweden. Second, we analyse the resource use and costs per severity level. Third, we analyse the relationship between costs and physician- and patient reported-outcome measures. Materials and methods: The study was based on Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study. The costs of healthcare contacts, drugs, formal and informal care, and productivity loss were collected over three months. Assessments at baseline were used for outcomes (EQ-5D, Hoehn and Yahr (H&Y), Schwab and England Scale, Unified Parkinson's Disease Rating Scale subscales (UPDRS) and Non-Motor Symptoms Scale (NMSS)). Costs were estimated in € 2016. Results: In total, 106 patients were included. The mean EQ-5D score in the total group was 0.24 (±0.33). The mean total cost excluding informal care per patient in the three-month period was approximately €14,097 (BCa 95% CI €12,007 and €16,039). Professional care accounted for the largest share (75 percent) of the total costs. The EQ-5D, H&Y, Schwab and England Scale, and NMSS were statistically significant predicting factors for total costs. Conclusion: Patients with late-stage PD are a vulnerable patient group that is costly to society and the impairment in patients’ HRQoL is immense. Thus, healthcare decision-makers should optimize the organization and provision of healthcare for these patients.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cost of illness, late-stage Parkinson's disease, quality of life, Sweden
in
Acta Neurologica Scandinavica
volume
145
issue
6
pages
743 - 752
publisher
Wiley-Blackwell
external identifiers
  • scopus:85126774584
  • pmid:35312034
ISSN
0001-6314
DOI
10.1111/ane.13611
language
English
LU publication?
yes
id
73350b2c-2ba9-41e4-9b57-599ecb717015
date added to LUP
2022-04-20 15:31:26
date last changed
2024-07-15 12:39:27
@article{73350b2c-2ba9-41e4-9b57-599ecb717015,
  abstract     = {{<p>Background: Few studies have investigated the health-related quality of life (HRQoL), resource use and costs in patients with late-stage Parkinson's disease (PD), and data from the Swedish setting are scarce. Objectives: First, we analyse the HRQoL in late-stage PD in Sweden. Second, we analyse the resource use and costs per severity level. Third, we analyse the relationship between costs and physician- and patient reported-outcome measures. Materials and methods: The study was based on Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study. The costs of healthcare contacts, drugs, formal and informal care, and productivity loss were collected over three months. Assessments at baseline were used for outcomes (EQ-5D, Hoehn and Yahr (H&amp;Y), Schwab and England Scale, Unified Parkinson's Disease Rating Scale subscales (UPDRS) and Non-Motor Symptoms Scale (NMSS)). Costs were estimated in € 2016. Results: In total, 106 patients were included. The mean EQ-5D score in the total group was 0.24 (±0.33). The mean total cost excluding informal care per patient in the three-month period was approximately €14,097 (BCa 95% CI €12,007 and €16,039). Professional care accounted for the largest share (75 percent) of the total costs. The EQ-5D, H&amp;Y, Schwab and England Scale, and NMSS were statistically significant predicting factors for total costs. Conclusion: Patients with late-stage PD are a vulnerable patient group that is costly to society and the impairment in patients’ HRQoL is immense. Thus, healthcare decision-makers should optimize the organization and provision of healthcare for these patients.</p>}},
  author       = {{M. Norlin, Jenny and Hjalte, Frida and Kruse, Christopher and Dodel, Richard and Rosqvist, Kristina and Odin, Per}},
  issn         = {{0001-6314}},
  keywords     = {{cost of illness; late-stage Parkinson's disease; quality of life; Sweden}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{743--752}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Acta Neurologica Scandinavica}},
  title        = {{Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study}},
  url          = {{http://dx.doi.org/10.1111/ane.13611}},
  doi          = {{10.1111/ane.13611}},
  volume       = {{145}},
  year         = {{2022}},
}